Nimble leaves Roche to commercialize chemical synthesis technology

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/Caiaimage/MartinBarraud)
(Image: Getty/Caiaimage/MartinBarraud)

Related tags: Roche, Chemical synthesis, Technology, Commercialization, Drug discovery, Drug development, Drug development process

Nimble Therapeutics spun out from parent company Roche to commercialize its chemical synthesis technology for drug discovery and development.

Nimble will operate as an independent business after Roche spun out the company and will look to establish strategic partnerships to jointly develop ‘unique’ drug candidates across various therapeutic areas, according to CEO, Jigar Patel.

Roche acquired Nimble​, then NimbleGen, in a $272.5m (€203m) deal in 2007. The Roche team that helped develop the chemical synthesis technology will join the fully independent company.

Board director at Nimble, Deval Lashkari, said in a statement, “The Roche team saw the value in separating the business to enable it to expand its platform and work on a variety of therapeutic areas with strategic partners.”

According to Nimble, the chemical synthesis technology platform can synthesize ‘millions’ of unique natural and modified peptide-based molecules.

Based in Madison, Wisconsin, Nimble has also developed biological assays that can be used for empirical optimization of molecules.

Related news

Related products

show more

Transforming Clinical Development

Transforming Clinical Development

PerkinElmer | 01-Jun-2021 | Technical / White Paper

The estimated cost of bringing a drug to market in the U.S. according to JAMA is $1 billion.1 The extreme cost of clinical trials urge biopharmaceutical,...

Vaccine Innovation in the Era of COVID19

Vaccine Innovation in the Era of COVID19

Covance Patient Safety | 01-Oct-2020 | Sponsored Link

During this time of worldwide crisis, there is an increasing demand for the acceleration of a vaccination for COVID19. Regardless of the great recent advancements...

Strategies to Achieve Successful Approval & Launch

Strategies to Achieve Successful Approval & Launch

Catalent Pharma Solutions | 03-Sep-2020 | Data Sheet

There are several key considerations to how companies should approach commercial-scale manufacturing that may aid the success of their biologic’s launch...

Single-Pass Tangential Flow Filtration

Single-Pass Tangential Flow Filtration

BioContinuum™ Platform - MilliporeSigma | 01-Aug-2020 | Application Note

Tangential flow filtration (TFF) is widely used in the biopharmaceutical industry for downstream processing applications. Typical TFF steps concentrate...

Related suppliers

Follow us


View more